Propel Bio Management LLC Purchases Shares of 49,000 Nektar Therapeutics $NKTR

by · The Markets Daily

Propel Bio Management LLC acquired a new position in shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 49,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,788,000. Nektar Therapeutics makes up about 2.8% of Propel Bio Management LLC’s holdings, making the stock its 12th biggest position.

A number of other institutional investors also recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter worth approximately $65,000. Integrated Wealth Concepts LLC acquired a new stake in Nektar Therapeutics during the 1st quarter valued at $68,000. Compass Wealth Management LLC bought a new position in Nektar Therapeutics in the 3rd quarter valued at $88,000. Bessemer Group Inc. boosted its stake in Nektar Therapeutics by 1,741.2% in the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 1,480 shares in the last quarter. Finally, Bayforest Capital Ltd bought a new stake in shares of Nektar Therapeutics during the third quarter worth $96,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Stock Up 4.4%

NASDAQ:NKTR opened at $71.11 on Thursday. Nektar Therapeutics has a 12-month low of $6.45 and a 12-month high of $75.67. The stock’s fifty day simple moving average is $49.49 and its 200-day simple moving average is $51.07. The firm has a market capitalization of $1.45 billion, a P/E ratio of -8.92 and a beta of 1.17.

Analysts Set New Price Targets

NKTR has been the subject of a number of research analyst reports. BTIG Research lifted their price target on Nektar Therapeutics from $118.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Citigroup assumed coverage on shares of Nektar Therapeutics in a research report on Wednesday, November 26th. They issued a “buy” rating and a $102.00 price objective for the company. William Blair upgraded shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Nektar Therapeutics in a research report on Wednesday, December 17th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.29.

Get Our Latest Research Report on NKTR

Insider Transactions at Nektar Therapeutics

In other news, CEO Howard W. Robin sold 423 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $73.00, for a total transaction of $30,879.00. Following the completion of the transaction, the chief executive officer directly owned 75,489 shares in the company, valued at approximately $5,510,697. The trade was a 0.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Zalevsky sold 3,867 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total value of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares of the company’s stock, valued at approximately $761,697.18. This trade represents a 15.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 4,470 shares of company stock worth $181,955. Company insiders own 5.25% of the company’s stock.

About Nektar Therapeutics

(Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.

Recommended Stories

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR – Free Report).